- Hims & Hers (HIMS, Financial) plans to launch a generic semaglutide in Canada, tapping into the expiring patent market.
- Analyst consensus gives HIMS a "Hold" recommendation with a 2.8 rating.
- Current projections show mixed prospects for HIMS with some suggesting a potential downside.
Hims & Hers Expansion Strategy
Hims & Hers (HIMS) is poised to disrupt the weight-loss market in Canada by introducing a generic version of semaglutide, the active compound in Novo Nordisk's (NVO) renowned weight-loss medication, Wegovy. This strategic move is set for next year, coinciding with the patent expiration of semaglutide in 2026. The initiative underscores Hims & Hers' commitment to affordable weight-loss solutions.
Wall Street Analysts Forecast
Market experts are closely watching Hims & Hers Health Inc (HIMS, Financial), with insights from 13 analysts painting a varied picture. The average one-year stock price target is $48.26, with forecasts ranging from a high of $85.00 to a low of $28.00. Currently trading at $50.19, the average target indicates a potential downside of 3.85%. For a deeper dive into these projections, visit the Hims & Hers Health Inc (HIMS) Forecast page.
Brokerage Recommendations
The consensus from 14 brokerage firms positions Hims & Hers Health Inc (HIMS, Financial) with a "Hold" rating, averaging a score of 2.8 on a scale where 1 is a Strong Buy and 5 is a Sell. This reflects moderate confidence in the company's short-term prospects.
GuruFocus Valuation Insights
According to GuruFocus, the GF Value for Hims & Hers Health Inc (HIMS, Financial) in the coming year is estimated at $35.48. This suggests a potential downside of 29.31% from the current trading price of $50.19. The GF Value considers historical trading multiples, past business growth, and anticipated future performance to gauge fair market value. For more comprehensive data, explore the Hims & Hers Health Inc (HIMS) Summary page.
